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Abstract
BACKGROUND—Epidemiological studies indicate that calcium channel blocker (CCB) use is 
inversely related to prostate cancer (PCa) incidence. The association between CCB use and PCa 
aggressiveness at the time of radical prostatectomy (RP) and outcome after RP was examined.
METHODS—Medication use, PCa aggressiveness and post-RP outcome were retrieved from a 
prospectively populated database that contains clinical and outcome for RP patients at Roswell 
Park Cancer Institute (RPCI) from 1993 to 2010. The database was queried for anti-hypertensive 
medication use at diagnosis for patients with ≥1 year follow-up. Recurrence was defined using 
NCCN guidelines. Chi-Square tests assessed the relationship between CCB use and PCa 
aggressiveness. Cox regression models compared the distribution of progression-free survival 
(PFS) and overall survival (OS) with adjustment for covariates. Results for association between 
CCB usage and PCa aggressiveness were validated using data from the population-based North 
Carolina-Louisiana Prostate Cancer Project (PCaP).
RESULTS—48%, 37%, and 15% of RPCI’s RP patients (n = 875) had low, intermediate, and 
high aggressive PCa, respectively. 104 (11%) had a history of CCB use. Patients taking CCBs 
were more likely to be older, have a higher BMI and use additional anti-hypertensive medications. 
Diagnostic PSA levels, PCa aggressiveness, and margin status were similar for CCB users and 
non-users. PFS and OS did not differ between the two groups. Tumor aggressiveness was 
associated with PFS. CCB use in the PCaP study population was not associated with PCa 
aggressiveness.
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CONCLUSIONS—CCB use is not associated with PCa aggressiveness at diagnosis, PFS or OS.
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INTRODUCTION
Hypertension has been proposed as a risk factor for the development of prostate cancer 
(PCa). The association between hypertension and elevated PCa risk has been attributed to 
common causes for both conditions, such as activation of the autonomic nervous system and 
the angiotensin–renin system [1–3]. Consequently, the possibility that use of 
antihypertensive drugs plays a role in the etiology of PCa has been explored by several 
groups. Some [1,4] but not all [5–8] studies indicated that use of such medication is 
associated with a reduced risk for developing PCa and have proposed the use of 
antihypertensives as a means to lower the incidence of PCa. Several antihypertensive drug 
classes have emerged for which the evidence for an association with decreased PCa risk is 
convincing. Specifically, population-based studies have reported on an inverse association 
between the use of calcium channel blockers (CCBs) and the probability of developing PCa 
[4]. More recently, a statistically significant decreasing trend in the risk for advanced PCa by 
cumulative dose and duration of CCB usage has been reported, which suggests that 
administration of CCBs can attenuate disease progression [9]. The latter findings are in line 
with conclusions from studies using preclinical PCa cell line models, which demonstrate that 
treatment of PCa cells with CCBs, either alone or in combination with other drugs, inhibits 
PCa cell proliferation and induces apoptosis [10–12]. These observations suggest that CCB 
usage may be advantageous for preventing PCa progression and could influence disease 
outcome. To date, no studies have been performed to determine whether using CCBs has an 
impact on the aggressiveness of PCa or disease outcome after RP. The association between 
CCB use and PCa aggressiveness, progression-free survival (PFS) and overall survival (OS) 
after RP was explored using two large data sets, a prospectively populated RP experience 
and a population-based PCa cohort.
MATERIALS AND METHODS
RPCI Study Population
Patients who undergo RP for treatment of clinically localized PCa at Roswell Park Cancer 
Institute (RPCI) are enrolled prospectively in an Institutional Review Board (IRB)-approved 
database that maintains clinical, pathological, and outcome data as part of a quality 
assurance program (IRB approval I198211). Eight hundred seventy-five patients who 
underwent RP between 1993 and 2010 and who have been followed ≥ 1 year were included 
in the study. Men who received androgen deprivation therapy or radiation therapy prior to 
RP were excluded. Routine follow-up consisted of office visits after 6 weeks, 6 months, and 
1 year that included PSA tests and examination. If pathology was favorable patients were 
followed annually for 4 years. If pathology was unfavorable patients were followed every 6 
months for 4 years then yearly for an additional 5 years. PCa recurrence was defined 
biochemically using NCCN criteria or clinically if adjuvant therapy was administered for 
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any reason [13]. Antihypertensive medication usage was collected via review of preoperative 
records in a manner that was blinded to the cancer-specific outcome. Antihypertensive 
medications that were assessed include CCBs, beta-blockers (BBs), and angiotensin-
converting enzyme inhibitors (ACEs). Medication use was collected also at last follow-up 
visit to verify continued antihypertensive usage. Medication dosages were not recorded. The 
RPCI patient cohort was stratified by clinical stage, tumor aggressiveness, age, and 
preoperative serum PSA values. Tumor aggressiveness was defined as high (Gleason sum 
≥8, or PSA > 20 ng/ml, or Gleason sum = 7 and stage cT3–cT4); low (Gleason sum < 7 and 
stages cT1–cT2, and PSA < 10 ng/ml); or intermediate (all other cases) [14]. The study and 
study protocol were approved by the RPCI IRB (IRB approval EDR194411).
PCaP Database
The relationship between CCB use and tumor aggressiveness was validated using 
information from the North Carolina-Louisiana Prostate Cancer Project (PCaP) database that 
contains data on 2,256 PCa patients of whom approximately half are Caucasian Americans 
and half are African-Americans. One of the primary goals of the population-based PCaP 
study is to investigate and compare the factors associated with PCa aggressiveness in 
African Americans and Caucasian Americans. The methodology of the PCaP study has been 
described [14]. Prescription medication, including anti-hypertensives, that was used by 
research subjects was recorded at an in home visit. PCa aggressiveness was assigned using 
the same criteria as for the RPCI cohort and medical information was gleaned from the 
medical record. Post-RP outcome data from PCaP study participants was not available for 
analysis.
Statistical Analysis
Patient characteristics for CCB users and non-users were compared using Fischer’s Exact 
test and Wilcoxon Rank Sum tests. Chi-Square test was used to assess the relationship 
between CCB use and PCa aggressiveness. For secondary (subgroup) analyses, patient 
groups were compared using Mann–Whitney U-test or Kruskal–Wallis and Chi-Square or 
Fisher’s exact tests for continuous and categorical variables, respectively. OS and PFS were 
summarized using Kaplan–Meier methodology. Log-Rank test was performed to compare 
PFS and OS. Cox regression models were used to adjust OS and PFS for covariates. All 
statistical analysis were conducted using SAS v9.3 (Cary, NC). A significance level of 0.05 
was considered for all tests.
RESULTS
Mean age of RPCI RP patients was 60 years (SD ± 7) and mean serum PSA value was 7.4 
ng/ml (SD ± 7.4). Mean BMI at time of surgery was 29 kg/m2 (SD, 4.71). Four hundred and 
seventy-four (54%) patients had clinical Gleason sum (GS) ≤6, 305 (35%) had GS 7 and 96 
(11%) patients had GS ≥8. Two hundred eighty-five (29%) patients reported family history 
of PCa. Median post-RP follow-up was 42 months.
One hundred and four (11%) patients reported using CCBs at the time of initial presentation. 
Twenty-three (3%) patients used CCB medication alone for the management of hypertension 
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while 81 (9%) patients combined CCB use with other hypertensive medications (BBs and 
ACEs). Two hundred sixty-seven (31%) patients were taking BBs or ACEs without 
concomitant CCB use. Seventy percent of patients reported CCB use at last follow-up. 
Patients taking CCBs were older (P = 0.023) and had higher BMIs (P = 0.006). CCB users 
were more likely to take other anti-hypertensive medications (P < 0.001). There was no 
difference in clinical stage and PSA at diagnosis between CCB users and non-users. CCB 
use did not affect PCa aggressiveness between the two groups (P = 0.88; Table I).
An independent analysis of data from the population-based PCaP study on 2,256 PCa 
patients was performed to validate these results. Compared to RPCI’s RP cohort, the PCaP 
study contained more African-American patients (50% compared to 9%) and a higher 
percentage of CCB users (24% compared to 11%). CCB users in the PCaP cohort were more 
likely to be older (P < 0.001), to be African-American (P < 0.001) and to use other 
antihypertensive medications (P < 0.001). Similar to the RPCI RP cohort, there was no 
association between use of CCB medication and PCa aggressiveness (P = 0.33; Table II). 
Subgroup analysis on the African-American patient group of the PCaP cohort confirmed the 
association between use of CCBs and age (P < 0.001), BMI (P < 0.001), and use of other 
blood pressure medication (P < 0.001). A difference in tumor aggressiveness (P = 0.51) or 
Gleason sum (P = 0.151) was not noted between CCB users and non-users (Table III). In the 
small subgroup of African-American patients in the RPCI cohort no association was found 
between CCB usage and patient characteristics (data not shown). Secondary analysis on the 
PCaP cohort as a whole was done to evaluate also the association between CCB use, family 
history, and PCa aggressiveness. Patients were divided into four groups based on reported 
family history for PCa (present and absent) and CCB usage (users and non-users). CCB non-
users without family history were more likely to present with high and low aggressive 
disease, whereas patients who used CCBs and had a family history of PCa presented with 
intermediate aggressive disease (P = 0.032; Table IV, data not shown). These associations 
were, however, not corroborated in the RPCI patient cohort (data not shown).
The association between use of CCBs and post-RP outcome was examined using RPCI 
cohort data. OS and PFS were similar between CCB users and nonusers (OS P = 0.7195, 
PFS P = 0.818) on univariate analysis (Fig. 1). No difference was found in OS and PFS 
between the two groups when adjusted for age and PCa aggressiveness (Fig. 2). PCa 
aggressiveness was associated with PFS (P < 0.001) but not OS (P = 0.188) in the 
multivariable model.
Subset analysis was performed following classification of the patients into four groups: 
those who used CCBs only (n = 23), those who were on other hypertensive medications 
(BBs and ACEs) only (n = 267), those who combined antihypertensive use (CCBs and BBs/
ACEs; n = 81) and those who did not take any antihypertensive medication (n = 504; Table 
V). Patients who were not on antihypertensive medication were younger (P = 0.001) and had 
lower BMI (P < 0.001). Patients taking CCB medications alone had less aggressive disease 
compared to patients taking both CCBs and other hypertensive medications (P = 0.035). 
There was no difference in OS (P = 0.37) and PFS (P = 0.234) among the four groups 
(Figure 3). No difference in OS (P = 0.499) and PFS (P = 0.438) was found after adjustment 
for age and PCa aggressiveness.
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Many studies have sought a relationship between use of CCBs and the development of PCa 
but this study is the first to evaluate the association between CCB usage and PCa 
aggressiveness, PFS and OS. Perron et al. [6] found no association between use of CCBs and 
incidence of PCa in a case–control population study on 13,326 men. Debes et al. [4], on the 
other hand, reported an inverse relationship between CCB usage and the probability of 
developing PCa. Similarly, data from the Cardiovascular Health Study indicated a 40% 
reduced PCa risk in men taking CCBs [1]. While the Cancer Prevention Study II Nutritional 
Cohort study reported that patients on antihypertensive medications were at a decreased risk 
for low grade PCa, when data were stratified by CCB use, no significant association 
remained between the use of the CCB class of antihypertensives and PCa incidence or 
aggressiveness [7]. Data from the General Practice Research Database in the UK identified 
1,093 patients with a new diagnosis of PCa over a 4-year period. When stratified by CCB 
use there was no difference in PCa incidence between the two groups [5]. Vezina et al. [8] 
evaluated the risk of PCa in Massachusetts tumor registry population and found no 
difference in incidence between CCB users non-users.
Independent analyses of two separate clinical databases, either containing information on 
men who underwent RP at RPCI or population-based data on men with newly diagnosed 
PCa, failed to reveal a link between use of these antihypertensives and PCa aggressiveness. 
In addition, no significant differences in PFS and OS were found between users and non-
users in the RPCI patient cohort. Men on CCB, or antihypertensive medication in general, 
may have better access to health care than those who are not and therefore are more likely to 
be screened for and diagnosed with PCa [9]. A more intense interaction with the health care 
system could explain the conflicting results obtained in epidemiological studies that assessed 
the relationship between CCB use and PCa incidence [15]. Health care access difficulties 
that confound interpretation of epidemiologic study results are less likely to have influenced 
this analysis of PCa aggressiveness, PFS and OS: all patients in the PCaP and RPCI cohort 
had histologically confirmed PCa and follow-up for patients who underwent RP at RPCI was 
performed consistently.
CCB use in the RP cohorts was associated with an elevated BMI. This is not surprising as 
BMI has been reported to have a linear correlation with systolic blood pressure [16]. Obesity 
has been associated also with resistant hypertension, that is, refractory hypertension despite 
administration of three antihypertensive drugs at full dose [17]. The relationship between 
resistant hypertension and obesity would lead to an increase in the incidence of CCB usage 
in obese patients, and an increase in the incidence of concomitant CCB use with other 
medications, as was found in this study.
A strength of this study is the validation of the findings on PCa aggressiveness between two 
separate and robust data sets. While the patient populations differed significantly in CCB use 
(11% in RPCI cohort vs. 24% in the PCaP dataset), analyses of both databases failed to 
reveal an association between CCB usage and disease aggressiveness. The difference in 
proportion of patients on CCB may be due to the inclusions of fewer African American men 
in the RPCI cohort. Approximately half of the participants in the PCaP study were African 
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American, who are more likely to be prescribed CCB as first line treatment for hypertension, 
compared to only 9% of patients at RPCI. The consistency in the results obtained from a 
population-based dataset (PCaP) and an RP cohort from a tertiary referral center (RPCI) 
further strengthens these findings. The results indicate that patients taking CCB alone (n = 
23) presented with less aggressive disease than those who combined use of CCB with other 
antihypertensive medication (n = 81). In view of the small number of patients in each group, 
the relevance and significance of these observations will need to be assessed in a larger 
cohort. Similarly, validation of the association between CCB use, family history and PCa 
aggressiveness that was observed in the PCaP cohort but not for RPCI patients, requires 
additional analyses of suitable patient cohorts.
The cross-sectional nature of data collection at the time of surgery prevented determination 
of the duration of CCB use prior to RP. This may have biased the results as patients who 
were on CCB medication for a short period of time prior to operation are considered CCB 
users without having experienced necessarily the physiological effects of long term CCB 
use. In theory, this could affect PCa aggressiveness at time of surgery, but should not affect 
evaluation of PFS and OS. In an attempt to mitigate this issue, patient records were reviewed 
to confirm use of CCB at the last follow-up visit. Approximately 70% of patients on CCB 
medications were still using them at last follow-up. This rate compares favorably to 
population-based studies. Van Wijk et al. [18] described 10-year discontinuation rates from a 
large population database of 2,325 antihypertensive users. At 4-year follow-up, 
approximately 53% of men in the study were using persistently the hypertensive medication 
prescribed originally. Additionally, data from NHANES demonstrate that in a PSA screening 
population, mean duration of CCB therapy was 5 years [19]. Therefore, despite the cross-
sectional nature of the medication data collection, a large proportion of men in our study 
group should have had adequate exposure to observe any effect on PCa aggressiveness, PFS, 
and OS.
PCa aggressiveness was associated with PFS but not OS. The reason for disparity between 
PFS and OS is likely due to relatively short duration of follow-up. Since the median length 
of time from operation to PCa-specific mortality and all causes mortality is approximately 9 
years, an association between tumor aggressiveness and OS was unlikely to be found [20]. 
Another limitation is the inability to determine whether there was a dose-dependent response 
to CCB medication use. Medication dosages were not collected at the time of RP and could 
not be used to stratify results based upon potential differences in CCB dosage.
CONCLUSIONS
This study was the first to explore the relationship between CCB use, which has been linked 
to PCa incidence, and PCa outcome. No association was found between usage of this class 
of antihypertensives and PCa aggressiveness at time of diagnosis, or post-RP PFS or OS.
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Unadjusted PFS and OS for RP RPCI cohort separated by CCB use.
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PFS and OS for RP RPCI cohort separated by CCB use and adjusted for age and tumor 
aggressiveness.
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PFS and OS for RP RPCI cohort separated by antihypertensive medication use and adjusted 
for age and tumor aggressiveness.
Poch et al. Page 11

























Poch et al. Page 12
TABLE I
Baseline Characteristics of the RPCIRP Cohort Separated by CCB Use
No CCB CCB P-value
Overall
 N (%)  771 (88) 104 (11)
Age
 Median (range)    60 (41–80)   62 (44–74)   0.023
BMI
 Median (range)    28 (19–49)   30 (20–51)   0.006
Family history of prostate cancer
 No  490 (70%)   72 (76%)
 Yes  209 (30%)   22 (23%)   0.23
Race
 White  699 (91%)   87 (85%)
 Other    72 (9%)   16 (15%)   0.56
Other antihypertensive medications
 No  504 (65%)   23 (22%)
 Yes  267 (35%)   81 (78%) <0.001
PSA
 Median (range) 5.44 (0.23–90)     5 (1.50–29)   0.97
Gleason sum
 <7  422 (55%)   52 (50%)
 7  266 (35%)   39 (37%)
 >7    83 (11%)   13 (12%)   0.61
Tumor T stage
 1  506 (66%)   66 (64%)
 2  249 (32%)   36 (35%)
 3–4    12 (1.6%)     1 (1.0%)   0.88
Tumor aggressiveness
 Low  373 (48%)   48 (46%)
 Intermediate  283 (37%)   41 (39%)
 High  115 (15%)   15 (14%)   0.88
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TABLE II
Baseline Characteristics of the PCaP Cohort Separated by CCB Use
No CCB CCB P Value
Overall
 N (%) 1,720 (76) 538 (24)
Age
 Median (range)      63 (41–79)   64 (41–79) <0.001
BMI
 Median (range)      28 (15–59)   30 (17–66) <0.001
Family history of prostate cancer
 No 1,170 (74%) 362 (75%)
 Yes    420 (26%) 121 (25%)   0.55
Race
 White    928 (54%) 200 (37%)
 Black    792 (46%) 338 (63%) <0.001
Other antihypertensive medications
 No 1,133 (66%) 206 (18%)
 Yes    587 (34%) 332 (61%) <0.001
PSA
 Median (range)        6 (0–4,520)     6 (0–2,000)   0.44
Gleason sum
 <7 1,036 (60%) 295 (55%)
 =7    487 (28%) 168 (31%)
 >7    197 (11%)   75 (14%)   0.07
Tumor T stage
 1    958 (57%) 274 (52%)
 2    689 (41%) 243 (47%)
 3–4      32 (2%)     6 (1%)   0.06
Tumor aggressiveness
 Low    853 (52%) 249 (48%)
 Intermediate    505 (31%) 170 (33%)
 High    295 (18%) 101 (19%)   0.33
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TABLE III
Baseline Characteristics in African-American PCaP Patients Separated by CCB Use
No CCB CCB P-value
Overall
 N (%) 792 (70) 338 (30)
Age
 Median (range)   61 (41–79)   63 (41–79) <0.001
BMI
 Median (range)   28 (16–49)   30 (17–67) <0.001
Family history of prostate cancer
 No 530 (73%) 219 (72%)
 Yes 194 (27%)   87 (28%)   0.59
Other antihypertensive medications
 No 521 (66%) 132 (39%)
 Yes 271 (34%) 206 (61%) <0.001
PSA
 Median (range)  6.0 (0.0–4,520.0)  6.0 (0.0–411.0)   0.54
Gleason sum
 <7 455 (57%) 173 (51%)
 7 237 (30%) 117 (35%)
 >7 100 (13%)   48 (14%)   0.15
Tumor T stage
 1 441 (57%) 173 (64%)
 2 311 (41%) 152 (35%)
 3–4   17 (2%)     3 (1%)   0.09
Tumor aggressiveness
 Low 353 (47%) 142 (44%)
 Intermediate 240 (32%) 115 (35%)
 High 160 (21%)   68 (21%)   0.51
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